Acadia Pharmaceuticals (ACAD) Tops Q3 EPS by 1c
More News related to ACAD
- ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 8, 2010
- Osteologix Announces Financing
- Acadia Pharmaceuticals (ACAD) Tops Q3 EPS by 1c
- ACADIA Pharma (ACAD) to Cut Workforce by 50%
- Unusual 11 Mid-Day Movers 10/06: FONR, ICTG, ACAD, AVCT Higher; MNKD, VRNMD, ARP, PPD Lower
More News related to Earnings
- Forrester Research (FORR) Posts Q4 EPS of $0.35 Tops by 7c; Guides Q110 and FY10
- NetSol (NTWK) Reports Q2 Loss of $0.01, Misses by 2c; Reaffirms Guidance
- Rentech (RTK) Reports Q1 Loss of $0.07
- Textainer (TGH) Tops Q4 Earnings Views
- Sprint Nextel (S) Q4 Losses Narrow, But Miss Expectations
Acadia Pharmaceuticals Inc. (NYSE: ACAD) reports a Q3 loss of $0.23, 1 cent better than the analyst estimate of ($0.24). Revenue for the quarter was $2.4 million, which compares to the estimate of $2 million.
Related Categories
EarningsStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
